Why the study?
Postpartum venous thromboembolism is an important cause of maternal mortality, but individual risk estimation remains challenging and dedicated randomized controlled trials for thromboprophylaxis are lacking.
Does postpartum low-dose low-molecular-weight heparin prevent venous thromboembolism in postpartum women?
Does postpartum low-dose low-molecular-weight heparin prevent venous thromboembolism in postpartum women?
This narrative review highlights contemporary evidence on risk stratification and prevention of postpartum VTE using low-molecular-weight heparins in intermediate and high-risk groups.
Precise individual postpartum VTE risk estimation remains challenging; leaves open the need for validated models and targeted prophylaxis trials.
The postpartum period represents the most critical time for pregnancy-associated venous thromboembolism (VTE), which is responsible for substantial morbidity and an important cause of maternal mortality. The estimated risk of postpartum VTE of about 1/1,000 deliveries can be modulated with the knowledge of maternal and obstetrical risk factors, although a precise estimate remains challenging in individuals. The use of postpartum low-dose low-molecular-weight heparins are tailored at intermediate and high-risk groups to reduce the thrombotic burden, despite the lack of dedicated randomized controlled trials. In this review, we will highlight the contemporary evidence on the risk of postpartum VTE, its stratification and its prevention. We will also discuss our knowledge on the values and preferences of women for postpartum thromboprophylaxis and their adherence to treatment.
No takes yet. Share an insight, caveat, or question.
Blondon et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: